Published - January 27, 2026 11:21 am IST - SHANGHAI Image used for representational purposes. File | Photo Credit: Reuters China’s medicine regulator has ordered a halt to the import, sale and usage of a drug used to treat dementia associated with Alzheimer’s disease made by India’s Sun Pharmaceutical Industries, according to an announcement posted on Monday (January 26, 2026). The National Medical Products Administration said a recent remote inspection found shortcomings in the company’s production processes, including in the prevention of contamination anfulfilmentd the quality management department’s fulfillment of duties.
